3-(2-methoxyethyl)-2-methyl-4,9-dioxo-1-(pyrazin-2-ylmethyl)naphtho[2,3-d]imidazol-1-ium bromide
| Title | Journal |
|---|---|
| YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells. | PloS one 20170101 |
| Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics. | Molecular oncology 20140501 |
| Inhibition of pluripotent stem cell-derived teratoma formation by small molecules. | Proceedings of the National Academy of Sciences of the United States of America 20130827 |
| Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab. | The Journal of pharmacology and experimental therapeutics 20121001 |
| Survivin is a therapeutic target in Merkel cell carcinoma. | Science translational medicine 20120509 |
| The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2. | Anticancer research 20120501 |
| A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20120401 |
| Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin. | Molecular cancer therapeutics 20120101 |
| Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263. | Biochemical pharmacology 20111101 |
| YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer. | International journal of oncology 20110901 |
| Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110815 |
| YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. | Anti-cancer drugs 20110601 |
| Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells. | PloS one 20110101 |
| Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. | British journal of cancer 20100629 |
| Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. | Drug metabolism and disposition: the biological fate of chemicals 20100101 |
| Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090601 |
| Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells. | Drug metabolism and disposition: the biological fate of chemicals 20090301 |
| Survivin expression in primary malignant melanoma of the esophagus. | Scandinavian journal of gastroenterology 20090101 |
| Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081110 |
| Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of YM155, a novel small-molecule survivin suppressant, in dog plasma. | Biomedical chromatography : BMC 20080701 |